Ukadike, Kennedy C.
Najjar, Rayan
Ni, Kathryn
Laine, Amanda
Wang, Xiaoxing
Bays, Alison
Taylor, Martin S.
LaCava, John
Mustelin, Tomas
Funding for this research was provided by:
NIH (AR075134, AR077266, and AR081654 (to T.M.), T32 AR007108 (to K.U and R.N.), R01GM126170 (to J.L.)., AR075134, AR077266, and AR081654 (to T.M.), T32 AR007108 (to K.U and R.N.), R01GM126170 (to J.L.)., AR075134, AR077266, and AR081654 (to T.M.), T32 AR007108 (to K.U and R.N.), R01GM126170 (to J.L.)., AR075134, AR077266, and AR081654 (to T.M.), T32 AR007108 (to K.U and R.N.), R01GM126170 (to J.L.).)
Article History
Received: 29 January 2023
Accepted: 4 May 2023
First Online: 10 May 2023
Declarations
:
: The study was approved by the institutional ethics board (STUDY00006196) and informed written consent was obtained from all participants according to the Declaration of Helsinki.
: Not applicable.
: TM reports consulting fees from Cugene, QiLu Biopharma, Miro Bio, and Rome Therapeutics. JL has equity in Rome Therapeutics and Oncolinea. MT also has equity in Rome Therapeutics.